Abstract:Genhao Zhang Department of Blood Transfusion, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China Correspondence: Genhao Zhang, Email Purpose: Complex crosstalk between tumor cells and platelets is closely related to the development, relapse, and drug resistance of hepatocellular carcinoma (HCC). Therefore, an intensive analysis of the relationship between platelet-related genes and the effectiveness of immunotherapy is necessary for improving the poor prognosis of HCC patients. Methods: Genes associated with platelets in the GeneCards database were collected and were used to identify molecular subtypes using a non-negative matrix decomposition algorithm (NMF) and constructed a platelet-related genes-based prognostic stratification model by the LASSO-Cox regression and stepwise Cox regression analysis. The effect of this feature on the immune microenvironment of HCC and the response to immune checkpoint inhibitors was also explored. Results: After identifying two molecular subtypes, we constructed a platelet-related genes-based prognostic stratification model that can be effectively used for immune checkpoint inhibitor (PD1, PD-L1, PD-L2, and CTLA4) efficacy and prognosis prediction in HCC patients, which was subsequently validated using patient samples from ICGC, GSE14520 and a small sample size clinical cohort. We also found downregulation of PAFAH1B3 remarkably inhibited the proliferation and migration ability of Hep3B cells by cytological experiments. Conclusion: We constructed a prognostic classifier based on platelet-related genes that could effectively classify HCC patients for prognostic prediction and provide new light on the selection of optimal individualized antiplatelet therapy for HCC patients in future clinical practice. Keywords: HCC, prognosis, immunotherapy, PAFAH1B3, NMF, platelet Platelets are small, non-nucleated blood cells produced by megakaryocytes in the bone marrow, which play an important role in clotting and maintaining hemostasis after mechanical injury to blood vessels. In recent years, an increasing number of studies have demonstrated the strong link between platelets and tumors. 1 Tumor cells can cause abnormal platelet counts as well as platelet activation and aggregation function through the release of endogenous thrombin, TXA2, and ADP. 2 Platelet counts are a prognostic predictor for patients with a variety of tumors, including lung, ovarian, prostate, colon cancers, and melanoma. 3–6 Tumor cells can also trigger platelet activation by modulating glycoprotein VI-mediated immunoreceptor tyrosine-based activation motif (ITAM) signaling, thereby regulating platelet adhesion, aggregation, and procoagulant activity. 7 Abnormal activation and aggregation of platelets, especially tumor-activated platelets aggregation, may lead to cancer-related thrombosis and facilitate vasculogenesis and tumor cell migration, which may cause death in cancer patients. 8–10 Interestingly, platelets contain a large number of bioactive molecules within them and express different receptors on their surface that can also, in turn, facilitate the growth and metastasis of tumors. 11,12 Platelets can secrete transforming growth factor beta (TGF-β) to increase the proliferation of ovarian cancer cells, and the proliferation capacity is diminished with TGF-β1 blocking antibodies. 13 Platelet granules contain various proangiogenic factors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), angiopoietin-1 and IL-6, which can induce intratumor blood vessel formation and promote the proliferation of tumor-associated pericytes in the tumor microenvironment (TME). 14–16 In addition, platelets can reduce E-cadherin levels and upregulate Snail, vimentin, and fibronectin levels in tumor cells, inducing invasive EMT phenotype, and promoting tumor cell metastasis. 16 In brief, there is a variety of crosstalk between platelets and cancer cells, and a deeper understanding of them can help clinicians develop strategies for the use of antiplatelet drugs in cancer prevention and treatment. Considering that cancer and platelet crosstalk is a complex process involving multiple genes, we constructed and validated a prognostic stratification model in public datasets based on the platelet-related genes which could be efficiently applied for prognostic categorization of HCC patients. In addition, we found that platelet-activating factor acetylhydrolase 1B catalytic subunit 3 (PAFAH1B3) was an independent prognostic factor in HCC patients and that reducing its expression inhibited tumor cell proliferation and migration. This study includes transcriptomic expression data an -Abstract Truncated-

A Three-Platelet Mrna Set: MAX, MTURN and HLA-B As Biomarker for Lung Cancer.

TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12 as novel biomarkers for lung cancer diagnosis and progression prediction

Interactive Verification Analysis of Multiple Sequencing Data for Identifying Potential Biomarker of Lung Adenocarcinoma

Platelet RNA Enables Accurate Detection of Ovarian Cancer: an Intercontinental, Biomarker Identification Study

Development and Validation of Tumor-educated Blood Platelets Integrin Alpha 2b (ITGA2B) RNA for Diagnosis and Prognosis of Non-small-cell Lung Cancer through RNA-seq

Genome-wide Microrna Expression Profiling in Malignant Pleural Effusion to Identify a Ten-Microrna Signature.

RNA Sequencing Enables Systematic Identification of Platelet Transcriptomic Alterations in NSCLC Patients

A Panel of Platelet Circrnas Serve As Biomarker for Lung Cancer Detection

Delivery of Platelet TPM3 Mrna into Breast Cancer Cells Via Microvesicles Enhances Metastasis.

Identifying and Analyzing Different Cancer Subtypes Using RNA-seq Data of Blood Platelets.

Predicting Lung Adenocarcinoma Prognosis with a Novel Risk Scoring Based on Platelet-Related Gene Expression.

A Novel Platelets-Related Gene Signature for Predicting Prognosis, Immune Features and Drug Sensitivity in Gastric Cancer

Platelet-Related Molecular Subtype to Predict Prognosis in Hepatocellular Carcinoma

Selection and Validation of Reference Genes for Pan-Cancer in Platelets Based on RNA-Sequence Data

Detection of circulating cancer cells in lung cancer patients with a panel of marker genes.

Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients

Identifying Common Genes Related to Platelet and Immunity for Lung Adenocarcinoma Prognosis Prediction

Evaluation of tumor-educated platelet long non-coding RNAs (lncRNAs) as potential diagnostic biomarkers for colorectal cancer

Characterization of platelet-related genes and constructing signature combined with immune-related genes for predicting outcomes and immunotherapy response in lung squamous cell carcinoma

Tumor-Educated Platelet RNA and Circulating Free RNA: Emerging Liquid Biopsy Markers for Different Tumor Types

Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer